Aldeyra's dry eye drug gets a rejection from the FDA
The FDA handed down a complete response letter to Aldeyra Therapeutics for its dry eye disease drug reproxalap, following months of speculation about whether the drug would be approved.
The company said the agency requested another clinical trial to investigate the drug’s efficacy further. Aldeyra had previously informed investors of that possibility earlier this year and said Monday that the proposed trial is estimated to cost less than $2 million, with topline data expected in the first half of next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.